Dr. Shore Comments on the Approval of Radium-223

Video

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Shore believes that the FDA approved radium-223 so quickly because of the robust data regarding efficacy and toleration. Radium-223 demonstrated an improvement in survival and delay in skeletal complications for patients with bone metastases and was well-tolerated, with no significant myelosuppression. As the radioisotope is cleared through the intestinal tract and excreted fecally, mild events of diarrhea were observed, Shore says.

Radium-223 is given intravenously over a period of about 45-60 seconds and is administered once every 4 weeks for 6 administrations. Additionally, Shore says, the agent must be administered by someone with the appropriate licensure.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD